IntegraGen SA

ENXTPA:ALINT Stock Report

Market Cap: €3.1m

IntegraGen Valuation

Is ALINT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALINT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALINT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALINT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALINT?

Key metric: As ALINT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALINT. This is calculated by dividing ALINT's market cap by their current revenue.
What is ALINT's PS Ratio?
PS Ratio0.2x
Sales€12.60m
Market Cap€3.11m

Price to Sales Ratio vs Peers

How does ALINT's PS Ratio compare to its peers?

The above table shows the PS ratio for ALINT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.4x
ALMDP Medesis Pharma
6.9xn/a€2.1m
ALCOX Nicox
4.4x-2.1%€15.7m
GV Genomic Vision Société Anonyme
0.4xn/a€692.9k
ALPRE Predilife
45.7xn/a€14.2m
ALINT IntegraGen
0.2xn/a€3.1m

Price-To-Sales vs Peers: ALINT is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (14.4x).

Price to Sales Ratio vs Industry

How does ALINT's PS Ratio compare vs other companies in the FR Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.4.4x32.4%
ALINT IntegraGen
 0.2xn/aUS$3.27m
ALGEN genOway Société anonyme
1.1xn/aUS$33.35m
LYS Lysogene
0.4xn/aUS$5.42m
ALINT 0.2xIndustry Avg. 4.4xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.4.4x5.0%
ALINT IntegraGen
 0.2xn/aUS$3.27m
No more companies

Price-To-Sales vs Industry: ALINT is good value based on its Price-To-Sales Ratio (0.2x) compared to the French Biotechs industry average (4.6x).

Price to Sales Ratio vs Fair Ratio

What is ALINT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALINT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALINT's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€118.3b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€94.40

7D

-1.4%

1Y

11.3%

Eurofins Scientific

€8.7b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.17

7D

1.5%

1Y

-12.0%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

-0.4%

1Y

-56.6%